Physician profile
Latisha T Rowe
NPI 1861657116
$10,518.83
in general payments reported to CMS, 2019-2025
13 companies · $9,079 in 2025
The $9,079 reported for 2025 was more than what 98% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $15.69 · 2021: $23.25 · 2022: $51.97 · 2023: $570 · 2024: $574 · 2025: $9,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,336 · Food and Beverage: $1,623 · Travel and Lodging: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,336.36 |
| Food and Beverage | $1,622.94 |
| Travel and Lodging | $1,263.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $9,322.33 | 2024-2025 | Yeztugo |
| Novo Nordisk INC | $468.80 | 2023-2024 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $177.19 | 2020-2024 | Krystexxa, Prolia, Evenity |
| Horizon Therapeutics Plc | $141.93 | 2023 | Krystexxa |
| Baxter Healthcare | $116.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $116.44 | 2019-2022 | |
| Lilly USA, LLC | $40.81 | 2024 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $29.96 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.70 | 2022 | |
| Lundbeck LLC | $23.36 | 2024 | Vyepti |
| Biotissue Holdings INC. | $23.25 | 2021 | |
| Exact Sciences Corporation | $19.39 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $14.79 | 2024 | Lux-Dx Insertable Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latisha Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.